IN2014DN05769A - - Google Patents

Info

Publication number
IN2014DN05769A
IN2014DN05769A IN5769DEN2014A IN2014DN05769A IN 2014DN05769 A IN2014DN05769 A IN 2014DN05769A IN 5769DEN2014 A IN5769DEN2014 A IN 5769DEN2014A IN 2014DN05769 A IN2014DN05769 A IN 2014DN05769A
Authority
IN
India
Prior art keywords
hippocampus
present
regenerating
mammal
defective
Prior art date
Application number
Other languages
English (en)
Inventor
Angel Lopez
Quenten Schwarz
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011905180A external-priority patent/AU2011905180A0/en
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of IN2014DN05769A publication Critical patent/IN2014DN05769A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5769DEN2014 2011-12-13 2012-12-13 IN2014DN05769A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011905180A AU2011905180A0 (en) 2011-12-13 Method of treatment
PCT/AU2012/001530 WO2013086574A1 (en) 2011-12-13 2012-12-13 Method of treatment

Publications (1)

Publication Number Publication Date
IN2014DN05769A true IN2014DN05769A (ko) 2015-04-10

Family

ID=48611719

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5769DEN2014 IN2014DN05769A (ko) 2011-12-13 2012-12-13

Country Status (9)

Country Link
US (1) US20140348793A1 (ko)
EP (1) EP2791324B1 (ko)
JP (1) JP2015500297A (ko)
KR (1) KR20140116103A (ko)
CN (1) CN104540938A (ko)
AU (1) AU2012350357A1 (ko)
CA (1) CA2859213A1 (ko)
IN (1) IN2014DN05769A (ko)
WO (1) WO2013086574A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006404A1 (en) * 2020-07-02 2022-01-06 The Johns Hopkins University Fmri-hippocampus acoustic battery (fhab)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003572A1 (en) * 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
ITNA20060017A1 (it) * 2006-02-20 2007-08-21 Aquino Riccardo D Tecnica di prelievo e selezione di un una popolazione di cellule staminali di tipo embrionale da tessuti follicolari peridentari di uomo adulto.
EP2531594B1 (en) * 2010-02-03 2016-11-16 Samsung Life Public Welfare Foundation Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling
EP2758778B1 (en) * 2011-09-22 2019-07-03 Precision Medicine Holdings Pty Ltd Screening method

Also Published As

Publication number Publication date
KR20140116103A (ko) 2014-10-01
AU2012350357A1 (en) 2014-07-24
JP2015500297A (ja) 2015-01-05
EP2791324A1 (en) 2014-10-22
US20140348793A1 (en) 2014-11-27
EP2791324A4 (en) 2015-04-29
CN104540938A (zh) 2015-04-22
CA2859213A1 (en) 2013-06-20
WO2013086574A1 (en) 2013-06-20
EP2791324B1 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MX2012001310A (es) Metodos para proporcionar efectos beneficos en la cavidad bucal.
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
IN2014DN06710A (ko)
MX2014000578A (es) Tratamiento con anticuerpos anti-pcsk9.
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
IL227919A0 (en) Methods and preparations for the production of stem cells related to highly active nerve cells specific to the patient
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
PT3153171T (pt) Samidorfano (alks 33) em combinação com buprenorfina para o tratamento de distúrbios depressivos
EA201490614A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB
PH12014500990A1 (en) Methods for treating gout flares
MX2015001488A (es) Tratamiento de la inflamacion utilizando serelaxina.
IN2015DN01137A (ko)
AU2016219603A1 (en) Method of treating the effects of stroke
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2012014163A (es) Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
SG195127A1 (en) Methods of treating or preventing neurological diseases
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази